Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 17,699 | 45,891 | 19,990 | 26,195 | 15,388 |
| Gross Profit | 17,699 | 45,891 | 19,990 | 26,195 | 15,388 |
| Operating Expenses | 27,182 | 25,879 | 26,445 | 28,920 | 29,822 |
| Operating Income | -9,483 | 20,012 | -6,455 | -2,725 | -14,434 |
| Interest Expense | 0 | 582 | 573 | 663 | 643 |
| Other Income | 3,013 | 53,638 | 4,139 | 76,594 | 939 |
| Pre-tax Income | -6,470 | 73,068 | -2,889 | 73,206 | -14,138 |
| Income Tax | -1,537 | 12,044 | -6,504 | 18,371 | -559 |
| Net Income Continuous | -4,933 | 61,024 | 3,615 | 54,835 | -13,579 |
| Net Income | $-4,933 | $61,024 | $3,615 | $54,835 | $-13,579 |
| EPS Basic Total Ops | -0.10 | 1.21 | 0.07 | 1.09 | -0.27 |
| EPS Basic Continuous Ops | -0.10 | 1.21 | 0.07 | 1.09 | -0.27 |
| EPS Diluted Total Ops | -0.10 | 1.18 | 0.07 | 1.08 | -0.27 |
| EPS Diluted Continuous Ops | -0.10 | 1.18 | 0.07 | 1.08 | -0.27 |
| EPS Diluted Before Non-Recurring Items | -0.06 | -0.03 | -0.03 | 1.08 | -0.27 |
| EBITDA(a) | $-9,704 | $19,101 | $-6,821 | $-2,738 | $-14,348 |